For laboratory research use only - not for human consumption

Hub · Perth Peptides Guide: Research, Delivery and WA Law

TB-500 in Perth

TB-500 here means Ac-LKKTETQ, a short fragment that Esposito and colleagues found in 2012 (Drug Testing and Analysis). It is not the whole thymosin beta-4 protein. The Form Laboratories catalogue records where the fragment sits in that protein, its freeze-dried form and its storage. Perth dispatch details are kept apart from the published lab and mouse research.

Published 2026-10-02Updated 2026-10-02Written by Form Laboratories research team9 min read

A chorus can stay in your head without being the whole song. A page can make sense without being the whole book. The same idea matters when you read about TB-500 in Perth. The Form Laboratories catalogue describes a piece of thymosin beta-4, not the whole protein. This part-and-whole question is what this page adds to the Perth research peptides hub.

Amino acids are the units that make up proteins, as the TGA explains in its April 2026 peptide advisory. For TB-500, the useful question is which units belong to the fragment and which belong to the parent. Keep those names apart and the papers are easier to read. A study of the whole protein does not become a study of the small piece just because the heading changes.

Catalogue listing: Buy TB-500 (research use only). For ordering, dispatch and lab reports, see buy TB-500 in Australia. For BPC-157, TB-500 and the blend together, see buy BPC-157 and TB-500 in Australia.

  • Guidethe Perth research peptides hubPeptides in Perth: research-use-only material, published delivery windows, available batch documentation and the Australian and WA legal framework.
  • TB-500 research vialResearch use onlyTB-500In stockBuy TB-500 (research use only)
  • Guidebuy TB-500 in AustraliaWhere to buy TB-500 in Australia as a research use only material. Online only, dispatched from Perth with tracking. What the certificate library lists for TB-500 and the BPC-157 and TB-500 blend.
  • Guidebuy BPC-157 and TB-500 in AustraliaWhere to buy BPC-157, TB-500 and the BPC-157 and TB-500 blend in Australia as research use only materials. Online only, dispatched from Perth with tracking.

Key facts

Key facts for TB-500 in Perth: the Thymosin Beta-4 Fragment
Common nameTB-500
Recorded identityAc-LKKTETQ fragment, Esposito et al., 2012
Fragment length7 amino acids, Form Laboratories catalogue
Parent positionResidues 17–23, catalogue; Esposito et al., 2012
Parent proteinThymosin beta-4; 43 amino acids, catalogue
CAS recordForm Laboratories TB-500 / CAS: report-checking note; read 2 October 2026
Binding studyVan Troys et al., EMBO Journal, 1996
Mouse studyPhilp et al., Wound Repair and Regeneration, 2003
Australian classificationSchedule 4; Appendix D clause 5 item 38; F2026L01327; checked 1 October 2026 UTC
Recorded formatFreeze-dried research reference, catalogue
Storage record2–8 C; dry; protected from light, catalogue
Form Laboratories catalogueEsposito et al. · 2012

What is TB-500?

TB-500 is the Ac-LKKTETQ fragment in the Form Laboratories catalogue. It has seven amino acids, at positions 17–23 of the parent protein, thymosin beta-4. The catalogue gives the parent 43 amino acids. So one count is for the full chain, and one is for a much shorter part. Esposito and colleagues identified the fragment in 2012, in an analytical study in Drug Testing and Analysis. These details describe one short sequence. They do not describe every substance with a similar name. Start with the piece itself: its letters, its length and its position.

The TB-500 research guide follows the papers behind this catalogue description. The difference is easy to lose in a headline. A paper can mention thymosin beta-4 without testing Ac-LKKTETQ. Check which molecule the methods name, and the paper stays tied to what it really studied. The parent and the fragment belong in the same discussion, but each needs its own label.

  • GuideTB-500 research guideA plain-English guide to TB-500: the actin-binding fragment of thymosin beta-4, what's been studied, and why it isn't the same as the full protein.
Van Troys et al. · 1996Philp et al. · 2003Esposito et al. · 2012Form Laboratories catalogue

Evidence limits

What are the limits of the TB-500 evidence here?

The TB-500 sources on this page cover binding experiments, chemical identification and a mouse wound model. They do not show a result in people. Van Troys and colleagues studied lab variants of the parent protein in 1996. Esposito's 2012 paper looked at the chemical identity of the fragment. Philp's 2003 study reported a synthetic short peptide in aged mice. Each asks a different question, with different materials and settings. On 2 October 2026 we read the CAS field in the Form Laboratories TB-500 catalogue. It held a report-checking note, not a CAS number. We show that gap here instead of filling it with a number we cannot support.

Set the limits before you look at the result. Chemical identification tells you what was found in a tested sample. It does not tell you what happens in a person. A mouse experiment reports what was seen in an animal. Neither kind of paper, on its own, shows that a catalogue material matches the sample in that paper. The CAS entry and the study setting are useful limits. Each points to a question that still needs its own evidence.

EMBO Journal · 1996Esposito et al. · 2012Form Laboratories catalogue

Why is TB-500 different from thymosin beta-4?

In this catalogue, TB-500 is a fragment, and thymosin beta-4 is the parent protein it comes from. The catalogue places Ac-LKKTETQ inside the larger chain. The fragment is only part of that chain. Van Troys and colleagues studied how full-length protein variants interact with actin in the EMBO Journal in 1996. They asked which regions take part in that interaction. Their lab work is about the structure of the parent. So its findings keep that label when you apply them to the fragment.

The Van Troys abstract describes a central motif at residues 17–22 and a separate starting region at residues 1–16 in the full-length lab variants. Esposito's 2012 work is about the 17–23 fragment instead. Keep the endpoints in view. The binding-study motif and the isolated fragment are related descriptions, not the same study object. The table below sets the two identities side by side. A shared stretch then does not hide the rest of the protein.

Drug Testing and Analysis · 2012Form Laboratories catalogue

How was the TB-500 fragment identified?

Esposito and colleagues identified Ac-LKKTETQ in TB-500 using lab analysis in a 2012 Drug Testing and Analysis paper. The abstract describes finding and identifying the short peptide in the studied material. The team also made the fragment in the lab. The key limit is the sample in that paper. The result gives a published chemical description of the fragment. It does not show what is in a different sample with the TB-500 name. So the sequence is more useful here than the name.

The TB-500 catalogue sends the CAS question to report checking (Form Laboratories record, read 2 October 2026). The quality article on how a lot record connects to paperwork explains how record matching works. That paperwork question is separate from Esposito's science. Putting the same short name on a paper's sample and on an order does not make them the same thing. This page draws no conclusion about the identity of a supplied batch.

  • Guidehow a lot record connects to paperworkA batch or lot number identifies one production run. What that code lets a researcher check, what it ties together, and where its verifying power stops.
Wound Repair and Regeneration · 2003Esposito et al. · 2012

What did the mouse fragment study report?

Philp and colleagues published a mouse wound study in Wound Repair and Regeneration in 2003. It tested full-length thymosin beta-4 and a synthetic LKKTETQ peptide in diabetic and aged mice. The findings belong to those animals and that study design. They are not evidence about a person or a catalogue vial. The short sequence reported is LKKTETQ. Esposito's paper names Ac-LKKTETQ. We keep each paper's own wording. Then the two are not quietly treated as one tested material.

The mouse study shows why the short region draws interest. It does not remove the identity gap. A fragment tested beside its parent in one animal model is not the same material. The study can be interesting without answering a question about people. Its value here is narrow: a named synthetic peptide, a named animal model and a finding kept inside the experiment.

TGA · 13 April 2026TGA and CMO · 19 June 2026Poisons Standard · F2026L01327

What has the TGA said about TB-500?

The TGA named TB-500 among its unapproved peptide examples on 13 April 2026. On 19 June 2026, the Chief Medical Officer and TGA stated that these peptide goods “have not been evaluated by the TGA for safety, quality or effectiveness.” These notices are about peptide products and public health. They are not about the part-and-whole question in the papers. Each statement keeps its date, so you can find the official record. The advisory and the joint statement sit beside the law below. Each source answers its own question.

Instrument F2026L01327 is the October 2026 Poisons Standard, checked on 1 October 2026 UTC. It lists TB-500 under Schedule 4, at Appendix D clause 5 item 38. It lists thymosin beta 4 under Schedule 4, at clause 5 item 39. The two entries keep the two names apart in the legal record. The article on how scheduling reaches Western Australia explains the state-law background. The class above is tied to the October instrument and its check date.

Sport Integrity Australia · retrieved 9 September 2026Esposito et al. · 2012

How does the sport listing name TB-500?

Sport Integrity Australia lists Thymosin Beta-4 (TB-500) as prohibited in sport, in the peptide-page record retrieved on 9 September 2026. The listing puts TB-500 in brackets after the name of the parent protein. That is worth noticing now that the fragment and the full protein are kept apart. The sport entry is a record about sport. Its label does not change the molecular description in Esposito's study or the catalogue. Read the official name beside the scientific one. A shared heading is not chemical evidence.

Form Laboratories catalogueForm Laboratories shipping page

How is TB-500 stored and dispatched from Perth?

The Form Laboratories catalogue records TB-500 as a freeze-dried research reference, stored at 2–8 C, dry and away from light. The shipping page says dispatch from Perth happens after the bank transfer has reached the supplier and been matched to the order. Certificates of Analysis are available on request. The catalogue CAS field asks for report checking. So the tests and the lot stated on a report matter. Storage, dispatch and the order record are separate details. None of them shows what the delivered material is.

The catalogue listing for the TB-500 reference material belongs with these records. The shipping record for our Perth peptides store says parcels travel inside Australia with Australia Post or CouriersPlease, in plain outer packaging. A tracking email follows handover. Certificates of Analysis are available on request. Dispatch and documents are separate records. The catalogue name, the published fragment sequence and a given report are three different records.

Comparison

TB-500 and thymosin beta-4: sequence, length, molecular description, characterisation paper and identity evidence.

Comparison: TB-500 in Perth: the Thymosin Beta-4 Fragment
CriterionTB-500 fragmentThymosin beta-4 parent
Sequence descriptionAc-LKKTETQ, Esposito et al., 2012Full-length thymosin beta-4 variants, Van Troys et al., 1996
Length7 residues in the catalogue43 units in the catalogue's parent description
What it isThe isolated short regionThe protein containing that region
Paper characterising itEsposito: chemical identification, 2012Van Troys: laboratory binding analysis, 1996
What identifies the study materialReported fragment sequence and analytical workFull-length variant description in the binding experiment

FAQ

Is TB-500 the same as thymosin beta-4?

No: the catalogue separates the seven-unit TB-500 fragment from its 43-unit parent, thymosin beta-4. A paper about the larger molecule stays labelled as parent-protein evidence. The fragment's link to the parent does not make the findings the same. The October Poisons Standard, F2026L01327, has separate Schedule 4 entries for TB-500 and thymosin beta 4. They are items 38 and 39 in Appendix D clause 5 (checked 1 October 2026 UTC). The April 2026 TGA notice lists TB-500 among its unapproved product examples.

What is the TB-500 sequence?

Esposito's 2012 chemical work reports Ac-LKKTETQ, matching the parent protein's positions 17 through 23. Philp's aged-mouse study reports LKKTETQ. We keep the exact sequence next to each study so it shows what that study actually describes.

What is TB-500's CAS number?

On 2 October 2026 we read the Form Laboratories catalogue field for TB-500 CAS. It said “Confirm against the lab report” where a number would go. The fragment has a published sequence description. This page does not infer the identity of a catalogue batch from that paper, or from a report sitting in an account.

Has TB-500 been studied in humans?

The TB-500 sources reviewed for this page on 2 October 2026 are Van Troys’ 1996 binding experiments, Esposito’s 2012 chemical study and Philp’s 2003 animal wound research. These papers give no human result for the catalogue material. The answer covers only these papers. We did not search all human research.

Is TB-500 banned in sport?

Yes: Sport Integrity Australia’s peptide record, retrieved 9 September 2026, names “Thymosin Beta-4 (TB-500)” in its prohibited sport listing. That parent-name label stays separate from the fragment identity that Esposito reported in 2012.

Citations

3 sources
  1. Van Troys M et al. EMBO Journal. 1996;15(2):201–210. The actin binding site of thymosin beta 4 mapped by mutational analysis..
    doi:10.1002/j.1460-2075.1996.tb00350.x

  2. Philp D et al. Wound Repair and Regeneration. 2003;11(1):19–24.
    doi:10.1046/j.1524-475X.2003.11105.x

  3. Esposito S et al. Drug Testing and Analysis. 2012;4(9):733–738. Synthesis and characterization of the N‐terminal acetylated 17‐23 fragment of thymosin beta 4 identified in TB‐500, a product suspected to possess doping potential.
    doi:10.1002/dta.1402

Written by

Form Laboratories research team

Perth, Western Australia. We supply research-use-only reference material.

Written in-house
These articles are written and maintained by our own research team, not by a named clinician.
Built from the record
Every figure comes from published literature, listed in full above with a link to the original paper.
No use directions
We describe what the research measured. We give no use directions, preparation steps or advice.

Form Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.

2026 Form Laboratories - Research use only - Perth WAPerth WA 6000 - dispatched Australia-wide via Australia Post or CouriersPlease